Vitrolife AB (Publ): Interim Report January-March 2016: Good Growth in All Regions

Regulatory News:

Vitrolife (STO:VITR)

· Sales amounted to SEK 187 (162) million, corresponding to an increase of 15 percent in SEK. Sales growth was 16 percent in local currency.

· Operating income before depreciation and amortization (EBITDA) amounted to SEK 62 (54) million, corresponding to a margin of 33 (33) percent. Operating income included one-time expenses of SEK 5 million related to the planned consolidation of the time-lapse business. Adjusted for this, the margin amounted to 36 percent.

· Launch of a new range of aspiration needles for oocyte retrieval.

· Net income amounted to SEK 39 (35) million, which gave earnings per share of SEK 1.77 (1.61).

Gothenburg, April 26, 2016

VITROLIFE AB (publ)

Thomas Axelsson, CEO

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 26, 2015 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160426005732/en/